Know Cancer

or
forgot password

An Open, Randomized Clinical Phase I/II Trial to Investigate Maximum Tolerated Dose, Efficacy, and Safety of Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma


Phase 1/Phase 2
18 Years
N/A
Open (Enrolling)
Both
Multiple Myeloma

Thank you

Trial Information

An Open, Randomized Clinical Phase I/II Trial to Investigate Maximum Tolerated Dose, Efficacy, and Safety of Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma


This is an open, randomized, multicenter, phase I/II study with a parallel group design
investigating an intravenous and an oral CY dosing schedule in combination with LEN and
low-dose DEX in patients with refractory or relapsed MM. In phase I MTD of CY will be
determined using a common dose escalation scheme with 3 to 6 patients per dose level. In
phase II, efficacy and safety of the treatment regimens at the MTD will be investigated in
20 patients.

Inclusion Criteria


INCLUSION CRITERIA

1. Understand and voluntarily sign an informed consent form.

2. Age at least 18 years at the time of signing the informed consent form.

3. Able to adhere to the study visit schedule and other protocol requirements.

4. Previously diagnosed with multiple myeloma based on standard criteria and requires
therapy for primary refractory disease or 1st - 3rd relapse because of progressive
disease (PD), defined as a 25% increase in M-protein, development of new or worsening
of existing lytic bone lesions or soft tissue plasmacytoma, or hypercalcemia (serum
calcium > 11.3 mg/dL), or clinical relapse from CR.

5. At least one measurable disease manifestation defined as follows:

- For secretory multiple myeloma, measurable disease is defined as any
quantifiable serum monoclonal protein value (generally, but not exclusively, >
1g/dL IgG M-protein or > 0.5 g/dL IgA) and, where applicable, urine light-chain
excretion of ≥ 200 mg/24 h.

- For oligo- or non-secretory multiple myeloma, measurable disease is defined by
the presence of soft tissue (not bone) plasmacytomas as determined by clinical
examination or applicable radiographs (i.e. MRI, CT-Scan) or a quantifiable
plasma cell infiltration of the bone marrow as determined by bone marrow biopsy.

6. ECOG performance status equal to or less than 2 at time of randomization/registration
(see Appendix I).

7. Laboratory test results within these ranges within 1 week prior to
randomization/registration:

- Absolute neutrophil count ≥ 1.5 x 109/L without the use of colony stimulating
factors within 14 days before the laboratory test.

- Platelet count ≥ 75 x 109/L without transfusion support within 14 days before
the laboratory test.

- Hemoglobin ≥ 7.5 g/dL (regardless of transfusion support or prior medication
with erythropoietin).

- Calculated creatinine clearance ≥ 50 mL/minute.

- Total bilirubin equal to or less than 1.5 mg/dL.

- AST (SGOT) and ALT (SGPT) equal to or less than 2,5 x ULN.

- Corrected serum calcium < 14 mg/dL (< 3.5 mmol/L).

8. Female subjects of childbearing potential must:

- Understand that the study medication could have a potential teratogenic risk

- Agree to use, and be able to comply with, effective contraception without
interruption, 4 weeks before starting study drug, throughout study drug therapy
(including dose interruptions) and for 4 weeks after the end of study drug
therapy, even if she has amenorrhoea. This applies unless the subject commits to
absolute and continued abstinence confirmed on a monthly basis. The following
are effective methods of contraception:

- Implant

- Levonorgestrel-releasing intrauterine system (IUS)

- Medroxyprogesterone acetate depot

- Tubal sterilisation

- Sexual intercourse with a vasectomised male partner only; vasectomy must be
confirmed by two negative semen analyses

- Ovulation inhibitory progesterone-only pills (i.e., desogestrel)

Combined oral contraceptive pills are not recommended. If a subject was using
combined oral contraception, she must switch to one of the methods above. The
increased risk of VTE continues for 4 to 6 weeks after stopping combined oral
contraception

Prophylactic antibiotics should be considered at the time of insertion particularly
in patients with neutropenia due to risk of infection

- Agree to have a medically supervised pregnancy test with a minimum sensitivity
of 25 mIU/ml not more than 3 days from the start of study medication once the
subject has been on effective contraception for at least 4 weeks. This
requirement also applies to women of childbearing potential who practice
complete and continued abstinence.

- Agree to have a medically supervised pregnancy test every 4 weeks including 4
weeks after the end of study treatment, except in the case of confirmed tubal
sterilization. These tests should be performed not more than 3 days before the
start of next treatment. This requirement also applies to women of childbearing
potential who practice complete and continued abstinence Male subjects must

- Agree to use condoms throughout study drug therapy, during any dose interruption
and for one week after cessation of study therapy if their partner is of
childbearing potential and has no contraception.

- Agree not to donate semen during study drug therapy and for one week after end
of study drug therapy.

All subjects must

- Agree to abstain from donating blood while taking study drug therapy and for one
week following discontinuation of study drug therapy.

- Agree not to share study medication with another person and to return all unused
study drug to the investigator.

9. Disease free of prior malignancies for ≥ 5 years with exception of currently treated
basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix
or breast

10. Able and willing to take heparin (usually low-molecular weight - LMWH) or low
acetylsalicylic acid (100 mg) daily as prophylactic anticoagulation.

11. Life-expectancy > 3 months.

EXCLUSION CRITERIA

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

2. Females, who are pregnant, calculate to get pregnant or are breast feeding (Lactating
females must agree not to breast feed while taking lenalidomide).

3. Any condition, including the presence of laboratory abnormalities, which places the
subject at an unacceptable risk if he/she were to participate in the study or
confounds the ability to interpret data from the study.

4. Patient currently is enrolled in another clinical research study or has been enrolled
in such a study within 4 weeks before randomization/registration and/or is receiving
an investigational agent for any reason or has received such an agent within 4 weeks
before randomization/registration.

5. Known hypersensitivity to thalidomide, dexamethasone, or cyclophosphamide or similar
drugs.

6. Any prior use of lenalidomide.

7. Concurrent use of other anti-cancer agents or treatments.

8. Known positive for HIV or infectious hepatitis, type A, B or C.

9. Any other chemotherapy or high-dose dexamethasone within 4 weeks before
randomization/registration.

10. Immunotherapy or antibody therapy within 8 weeks before randomization/registration.

11. Major surgery within 4 weeks before randomization/registration.

12. Myocardial infarction within 6 months before randomization/registration, New York
Heart Association Class III or IV heart failure, uncontrolled angina, severe
uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
ischemia or active conduction system abnormalities.

13. Cardiac amyloidosis.

14. Poorly controlled hypertension, diabetes mellitus, or other serious medical or
psychiatric illness that could potentially interfere with the completion of treatment
according to the protocol.

15. Any systemic infection requiring treatment.

16. Cystitis.

17. Disturbance of urinary flow.

18. Unable or unwilling to take heparin (usually low-molecular weight - LMWH) or low
acetylsalicylic acid (100 mg) daily as prophylactic anticoagulation.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the maximum tolerated dose (MTD) of CY (PO and IV) in combination with LEN/low-dose DEX

Outcome Time Frame:

3 years

Safety Issue:

Yes

Principal Investigator

Martin Kropff, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Münster, Department of Hematology/Oncology

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

RV-MM-DSMM-0279

NCT ID:

NCT01019174

Start Date:

November 2009

Completion Date:

December 2013

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location